Table 2 Clinical outcomes for HER2-positive breast cancer by regimen
Doxorubicin, cyclophosphamide, docetaxel, trastuzumab plus pertuzumab (n = 40) | Doxorubicin, cyclophosphamide, docetaxel plus trastuzumab (n = 54) | P-value (chi square test) | |
|---|---|---|---|
Pathological complete response | |||
ypT0/is ypN0 | 18 (45.0%) | 18 (33.3%) | 0.250 |
Breast | 20 (50.0%) | 22 (40.7%) | 0.372 |
Axilla | 24 (60.0%) | 26 (48.1%) | 0.255 |